NDAINJECTIONINJECTABLE
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
DOCETAXEL (docetaxel) by Fosun Pharma is functions. Approved for breast cancer, non-small cell lung cancer, prostate cancer and 1 more indications. First approved in 2011.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a microtubule-stabilizing chemotherapy agent approved in 2011 for treatment of 18+ solid tumor types including breast, lung, prostate, and gastric cancers. It binds to tubulin and promotes stable microtubule assembly while inhibiting disassembly, leading to mitotic arrest and cell death. The drug represents a cornerstone taxane therapy across multiple oncology indications.
$0.013BPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $13K, this mature generic faces declining revenue; commercial teams are likely focused on cost management and operational efficiency rather than growth.
Mechanism of Action
functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…
Pharmacologic Class:
Microtubule Inhibitor
Indications (4)
Worked on DOCETAXEL at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.